Exon 44 Duchenne Muscular Dystrophy Cyclic Peptide Antisense

The USPTO published patent application US20260098262A9 for compounds and methods designed to skip exon 44 of the DMD gene using cyclic peptide antisense compositions. The application covers therapeutic compositions comprising both cyclic peptides and antisense compounds targeting pre-mRNA sequences. No prior similar patent by the same inventors is referenced.

Pharmaceutical companies and biotechnology firms developing exon-skipping therapies for Duchenne Muscular Dystrophy should monitor this application's prosecution for potential impact on freedom-to-operate analyses. This publication does not impose compliance obligations or deadlines. Competitors pursuing similar DMD exon-skipping approaches may need to evaluate whether this application's claims overlap with their own development programs.